Arvinas
Total Raised
$114.85MInvestors Count
27Deal Terms
3Funding, Valuation & Revenue
9 Fundings
Arvinas has raised $114.85M over 9 rounds.
Arvinas's latest funding round was a PIPE - II for $350M on November 27, 2023.
Arvinas's valuation in September 2018 was $514.53M.
Arvinas's 2020 revenue was $21.8M. Arvinas's most recent revenue is from 2020.
Sign up for a free demo to see revenue data from 2023 and more.
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
|---|---|---|---|---|---|---|
11/27/2023 | PIPE - II | $350M | EcoR1 Capital, RTW Investments, Adage Capital Management, ArrowMark Partners, Avidity Partners, BB Biotech Ventures, Boxer Capital, Citadel, Great Point Partners, Nextech Invest, RA Capital Management, Surveyor Capital, and Undisclosed Investors | 2 | ||
6/5/2019 | PIPE | $21.8M FY 2020 | ||||
9/27/2018 | IPO | $514.53M | ||||
4/4/2018 | Series C | |||||
10/21/2015 | Series B |
Date | 11/27/2023 | 6/5/2019 | 9/27/2018 | 4/4/2018 | 10/21/2015 |
|---|---|---|---|---|---|
Round | PIPE - II | PIPE | IPO | Series C | Series B |
Amount | $350M | ||||
Investors | EcoR1 Capital, RTW Investments, Adage Capital Management, ArrowMark Partners, Avidity Partners, BB Biotech Ventures, Boxer Capital, Citadel, Great Point Partners, Nextech Invest, RA Capital Management, Surveyor Capital, and Undisclosed Investors | ||||
Valuation | $514.53M | ||||
Revenue | $21.8M FY 2020 | ||||
Sources | 2 |
Arvinas Deal Terms
3 Deal Terms
Arvinas's deal structure is available for 3 funding rounds, including their IPO from September 27, 2018.
Round | IPO | Series B | Series A |
|---|---|---|---|
Funding Date | |||
Pre-Money Valuation | |||
Post-Money Valuation | |||
Amount Raised | |||
Shares Authorized | |||
Issuance Price | |||
Dividend Rate | |||
Liquidation Preferences | |||
Liquidation Price | |||
Participation | |||
Conversion Price | |||
Anti Dilution | |||
General Voting | |||
Board Voting | |||
Par Value |
Round | Funding Date | Pre-Money Valuation | Post-Money Valuation | Amount Raised | Shares Authorized | Issuance Price | Dividend Rate | Liquidation Preferences | Liquidation Price | Participation | Conversion Price | Anti Dilution | General Voting | Board Voting | Par Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
IPO | |||||||||||||||
Series B | |||||||||||||||
Series A |
Arvinas Investors
27 Investors
Arvinas has 27 investors. RA Capital Management invested in Arvinas's PIPE - II funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
|---|---|---|---|---|---|---|
10/21/2015 | 11/27/2023 | 3 Series B, Series C (2018), PIPE - II (2023) | Asset/Investment Management | Massachusetts | ||
4/4/2018 | 11/27/2023 | 2 Series C, PIPE - II (2023) | Venture Capital | Switzerland | ||
11/27/2023 | 11/27/2023 | 1 PIPE - II | Venture Capital | Switzerland | ||
Private Equity | Connecticut | |||||
Hedge Fund | New York |
First funding | 10/21/2015 | 4/4/2018 | 11/27/2023 | ||
|---|---|---|---|---|---|
Last Funding | 11/27/2023 | 11/27/2023 | 11/27/2023 | ||
Investor | |||||
Rounds | 3 Series B, Series C (2018), PIPE - II (2023) | 2 Series C, PIPE - II (2023) | 1 PIPE - II | ||
Board Seats | |||||
Type | Asset/Investment Management | Venture Capital | Venture Capital | Private Equity | Hedge Fund |
Location | Massachusetts | Switzerland | Switzerland | Connecticut | New York |
Compare Arvinas to Competitors
Amphista Therapeutics specializes in the development of targeted protein degradation (TPD) medicines within the biopharmaceutical sector. The company's offerings include engineered drugs that aim to destroy and remove pathogenic proteins associated with various diseases, using Targeted Glues technology. Amphista Therapeutics serves the pharmaceutical industry with a focus on developing new medicines. It was founded in 2017 and is based in Cambridge, England.
Pin Therapeutics develops therapeutic products in the biotechnology sector. They create products that degrade proteins associated with diseases. It was founded in 2017 and is based in Gyeonggi-do, South Korea.
Kymera Therapeutics (NASDAQ: KYMR) is a clinical-stage biotechnology company that focuses on developing medicines through targeted protein degradation. The company specializes in creating small-molecule therapies that target disease drivers, with an emphasis on immunological diseases and oncology programs. Kymera's approach aims to provide treatments for conditions that conventional therapeutics have struggled to address. It was founded in 2016 and is based in Watertown, Massachusetts.
Nurix Therapeutics is a biopharmaceutical company engaged in the development of degrader-based medicines within the healthcare sector. The company works on targeted protein degradation, aiming to address disease-causing proteins by utilizing the cell's natural protein degradation machinery. It offers Degrader-Antibody Conjugates (DACs) that combine antibodies with degraders. Nurix Therapeutics targets the cancer and autoimmune disease treatment sectors. It was founded in 2012 and is based in San Francisco, California.
C4 Therapeutics is a clinical-stage biopharmaceutical company focused on targeted protein degradation within the healthcare sector. The company develops small-molecule medicines designed to target and degrade disease-causing proteins, particularly in oncology. C4 Therapeutics utilizes its TORPEDO platform to create and optimize these medicines. It was founded in 2015 and is based in Watertown, Massachusetts.
Fimecs is a biopharmaceutical venture that focuses on the research and development of new drugs based on targeted protein degradation within the pharmaceutical industry. The company advances multiple drug development programs targeting proteins previously considered undruggable. The company was founded in 2018 and is based in Fujisawa, Japan. In February 2024, Fimecs was acquired by RaQualia Pharma.
Loading...